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Abstract: Surgical interventional strategies for the treatment of obesity are being implemented 
at an increasing rate. The safety and feasibility of these procedures are questionable for most 
overweight or obese individuals. The use of long-term pharmacotherapy options, on the other 
hand, can target a greater portion of the obese population and provide early intervention to help 
individuals maintain a healthy lifestyle to promote weight loss. Medications that act on the central 
serotonergic pathways have been a relative mainstay for the treatment of obesity for the last 
35 years. The clinical efficacy of these drugs, however, has been encumbered by the potential 
for drug-associated complications. Two drugs that act, albeit by different mechanisms, on the 
central serotonergic system to reduce food intake and decrease body weight are sibutramine and 
lorcaserin. Sibutramine is a serotonin and norepinephrine reuptake inhibitor, whereas lorcaserin 
is a selective 5HT2C receptor agonist. The recent worldwide withdrawal of sibutramine and FDA 
rejection of lorcaserin has changed the landscape not only for serotonin-based therapeutics 
specifically, but for obesity pharmacotherapy in general. The purpose of this review is to focus 
on the importance of the serotonergic system in the control of feeding and its potential as a 
target for obesity pharmacotherapy. Advances in refining and screening more selective receptor 
agonists and a better understanding of the potential off-target effects of serotonergic drugs are 
needed to produce beneficial pharmacotherapy.
Keywords: 5-hydroxytryptamine, serotonin 1B, fenfluramine, dexfenfluramine, satiety, 
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Introduction
Obesity in the past several decades has become increasingly prevalent in the adult 
population of several countries, such as the US, Mexico, and the UK.1–3 The alarming 
rate of childhood obesity in these and other countries only exaggerates the health 
concern worldwide.4–6 In fact, the World Health Organization projects 700   million 
adults will be clinically obese (BMI $ 30, body mass index; kg/m2) by 2015.7,8 
Individuals who are obese or even overweight (BMI 25–29.9) are at an increased 
risk of developing one or more chronic diseases, including diabetes mellitus type II, 
coronary heart disease, hypertension, and various cancers.9–11 Several studies have 
indicated that weight loss, even a 5% to 10% weight reduction, either lowers the 
risk of developing these comorbidities or helps in their therapeutic management.12–16 
The overall societal healthcare burden and the individual risk to a person’s health and 
wellbeing caused by excessive weight gain, therefore, can be dramatically reduced by 
effective interventional strategies aimed at reducing body weight.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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The type and degree of interventional strategies 
  recommended by a clinician to treat obesity can vary 
depending on the severity of weight gain and obesity-related 
  complications. The initial approach involves having patients 
reduce their total caloric intake by eating more nutritious foods 
while increasing their physical activity. Other behavioral 
approaches may involve self-monitoring of eating behaviors, 
cognitive therapies, and lifestyle modification support.12 
In addition, pharmacotherapy can be initiated if moderately 
overweight individuals (BMI 27–29.9) have   difficulty losing 
weight or are at a high risk for developing an obesity-related 
comorbidity. Pharmacotherapy is typically initiated in obese 
individuals with a BMI of $30 as part of a comprehensive 
treatment approach.12,17 In more severe obese individuals 
with a BMI of .40 (also known as class III obese) or a 
BMI . 35 with one or more obesity-related comorbidities, 
bariatric surgical options are considered as well.12,13,18,19 
  Bariatric surgery, in particular gastric bypass, compared with 
other interventional strategies is the most   clinically   effective 
at decreasing body weight and reducing the incidence and 
risk of most obesity-related comorbidities.19–21 Bariatric 
surgery, however, poses a   mortality risk (as high as 10%) 
to patients undergoing the procedure and the immediate and 
the   long-term cost-effectiveness is only significantly appar-
ent in individuals with a BMI $ 40.22–24 In addition, there 
is a suggested higher risk of suicide in patients undergoing 
bariatric surgery. A recent survey of 16,683 bariatric opera-
tions found there were 31 suicides in the 3-year post-surgery 
period (13.7 per 10,000 among men and 5.2 per 10,000 among 
women), which is a much higher rate than general age and 
sex-matched population in the US (2.4 per 10,000 among 
men and 0.7 per 10,000 among women).25 Nonetheless, obese 
individuals with a BMI $ 40 represent only 10% to 12% of 
the adult overweight or obese population in the US, suggesting 
that bariatric surgery is not a feasible weight loss interven-
tional strategy for most of the afflicted population.26 Hence, 
overweight or moderately obese individuals would benefit 
tremendously from effective pharmacotherapy before their 
weight gain becomes unmanageable or they develop associ-
ated comorbidities. When combined with other interventional 
strategies, in this sense, pharmacotherapy can help achieve or 
maintain ideal weight loss and possibly avoid more invasive 
life-threatening surgical interventions.
The development of effective long-term pharmacotherapy 
for obesity is a difficult task because mechanisms that promote 
sustained weight loss are often accompanied by mild to severe 
adverse events. The purpose of this review is to primarily 
focus on two obesity medications, sibutramine and lorcaserin, 
which act on the central serotonergic systems to reduce body 
weight. While the relevance of pharmacotherapy for obesity 
is certain to change in the next few years,   particularly as a 
consequence of the withdrawal of sibutramine and an FDA 
advisory panel’s concerns over lorcaserin, this review will 
highlight the importance of serotonergic systems and the 
pharmacotherapy potential for serotonergic drugs in the 
long-term treatment of obesity.
Pharmacotherapy for the long-term 
treatment of obesity
The clinical endpoint for effective pharmacotherapy, as 
  stipulated by the Food and Drug Administration (FDA, USA) 
and National Institute for Health and Clinical   Excellence 
(NICE, UK), is based on mean efficacy and categorical 
  efficacy. Mean efficacy is defined as a medication-associated 
(ie, greater than placebo) weight reduction of 5%.   Categorical 
efficacy is defined as a significantly greater proportion 
(at least 35%) of those individuals receiving the medication 
compared with placebo controls maintaining a 5% weight 
loss from their initial weight.13,27 A mean efficacy of a 5% 
medication-associated weight reduction has been a difficult 
criterion to achieve in most large scale clinical trials and an 
overall efficacy of a medication is generally assessed more 
by a risk-benefit approach. Until fall 2010, the only two pre-
scribed medications for the long-term treatment of obesity 
were orlistat and sibutramine. These drugs have completely 
different mechanisms of action, but each has shown to pro-
duce a varying degree of clinical efficacy at reducing body 
weight when administered along with interventional strate-
gies aimed at changing a patient’s diet, physical activity, and 
eating behaviors.
Orlistat or tetrahydrolipstatin is a derivative of lipstatin, an 
inhibitor of lipases isolated from the Gram-positive bacterium 
Streptomyces toxytricini.28 Orlistat reduces the absorption of 
dietary fat by selectively and irreversibly binding to pancre-
atic and gastric lipases in the intestinal lumen.   Inhibition of 
these lipases prevents the breakdown of triglycerides and 
diacylglycerides into free fatty acids for epithelial absorption 
and   subsequent utilization.29 Orlistat (120 mg 3 times daily) 
reduces the absorption of dietary fat by approximately 30% 
and has been demonstrated to result in an approximately 
3% greater orlistat-associated reduction in body weight in 
  long-term (52-week) randomized   double-blinded studies.30–32 
The most commonly reported adverse events with orlistat 
treatment in a large number of subjects (as high as 30% 
above the control group) were related to mild to moderate 
  gastrointestinal disturbances.30 Aside from rare cases of Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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acute liver injury, orlistat is a   moderately well-  tolerated, 
  relatively safe drug   producing modest long-term weight loss.33 
A   similar favorable assessment of orlistat’s risk-benefit 
analysis is shared by drug regulatory agencies in the US, 
European Union, and Australia, which have all approved 
  over-the-counter dosages of the drug.33–35
Sibutramine, on the other hand, was indefinitely 
  suspended in August 2010 for the treatment of obesity by 
the European Union drug regulatory agency based on several 
reports of cardiovascular complications; the agency cited 
the “drug’s benefits do not outweigh the risks”.36 In October 
2010,   following the findings of a comprehensive study 
examining the potential cardiovascular risks and a split 
decision of an FDA advisory panel, Abbott Laboratories, the 
manufacturers of sibutramine, withdrew sibutramine from 
the US, Australia, and other countries.37 Sibutramine is in 
a class of drugs known as monoamine reuptake inhibitors 
and most drugs of this class are prescribed for the treatment 
of depression.38–40 The effectiveness of monoamine reuptake 
inhibitors is achieved by augmenting central nervous   system 
(CNS) concentrations of monoamine neurotransmitters, 
such as dopamine (DA), norepinephrine (NE), and serotonin 
  (5-hydroxytryptamine; 5HT). Sibutramine was ineffective in 
vivo as an antidepressant, but produced   sustained weight loss 
by reducing food intake and increasing energy expenditure.38,41 
Sibutramine and its active amine metabolites alter seroton-
ergic and noradrenergic, but not dopaminergic, activity in 
brain areas that are involved in the control of appetite.38,42,43 
Long-term treatment (∼52 weeks) with sibutramine (10 or 
15 mg once daily) in randomized placebo-controlled studies 
has been shown to reduce body weight by 5% to 10% more 
than placebo control subjects.44,45 A meta-analysis examining 
10 long-term weight-loss studies with sibutramine (15 mg 
once daily), however, found more modest weight loss, with 
a 4.3% sibutramine-associated reduction in body weight.17 
Since its FDA approval in 1997, the widespread use of 
sibutramine to treat obesity was   limited because the drug 
increased heart rate and blood pressure and was not indicated 
in obese or overweight patients with a history of cardiovascu-
lar disease.46,47 Prompting the withdrawal of sibutramine was 
a recently completed multicenter trial examining sibutramine 
on   cardiovascular OUTcomes (SCOUT) in subjects with 
either a history of at least one risk factor for cardiovascular 
disease. The findings from this study demonstrated an overall 
16% increase in the relative risk of cardiovascular events (ie, 
nonfatal myocardial  infarction and stroke) with sibutramine 
treatment. Moreover, the sibutramine-associated weight 
loss at the end of the trial was modest, with approximately 
3% greater weight loss than the placebo group.48 The small 
weight-loss benefit and increased risk of cardiovascular 
events in at risk obese patients in such a large study led to 
an unfavorable assessment by an FDA advisory panel and 
subsequent withdrawal of the medication.
Lorcaserin (ADP356) is another potential treatment 
for obesity that acts on the central serotonergic system 
to reduce food intake and body weight. Lorcaserin is 
a selective serotonin receptor (5HT2C) agonist and is 
believed to reduce food intake predominantly by influ-
encing hypothalamic pathways involved in appetite.49 In 
a phase III clinical trial with 3182 overweight or obese 
subjects (known as BLOOM; Behavioral modification 
and Lorcaserin for Overweight and Obesity Management), 
there was a 4% lorcaserin (10 mg twice daily)-associated 
weight reduction at 52 weeks. Despite this modest weight 
loss, lorcaserin was associated with few subject-reported 
and no cardiovascular-related adverse events.50 The toxicol-
ogy data in rodents presented to the FDA advisory panel, 
however, demonstrated a significant number of neoplasms 
in mammary and brain tissue of rats treated with lorcaserin 
(10 mg/kg, 30 mg/kg, 100 mg/kg per day) for 2 years.51 
Based on the modest weight loss and the problematic 
carcinogenicity findings, the FDA advisory panel recom-
mended that lorcaserin not be approved for the long-term 
treatment of obesity, and that decision was supported by the 
FDA’s complete response letter to the New Drug Applica-
tion (NDA) filed for lorcaserin, which requested more data 
addressing these issues.52
Serotonin in the control of feeding 
behavior and metabolism
Serotonin (5HT) was initially isolated from beef serum in 
1948 during the process of determining an active substance 
involved in vasoconstriction.53,54 Although 5HT has extensive 
biological actions in peripheral tissue and as a vasoactive 
amine, its role as a neurotransmitter in the CNS as a modulator 
of behavior and mood has received considerable attention.55 
The 5HT-containing neurons are organized into nine nuclei 
(B1–B9) and are located in the midbrain and hindbrain 
areas. The dorsal raphe (B7), in particular, is a   midbrain 
nucleus that contains a substantial portion of the total brain 
5HT and has distinct projections to hypothalamic nuclei and 
other feeding-related forebrain areas.56,57 Obesity, either by 
genetic or diet-induced means, has been demonstrated to 
alter 5HT dorsal raphe neurons and 5HT terminal regions. 
For instance, the genetic obese fatty Zucker rats were shown 
to have hyperexcitable dorsal raphe neurons and greater Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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feeding-induced hypothalamic 5HT levels compared with lean 
Zucker rats.58,59 Continuous infusions (14-day) of 5HT into a 
target hypothalamic region, ventromedial nucleus, has been 
shown to reduce food intake and body weight of lean Zucker 
rats, but not obese Zucker rats.60 Related to this, increases 
in 5HT transporter binding have been reported in the dorsal 
raphe of rats made obese by feeding a high-energy diet (68% 
carbohydrate and 13% fat) for 7 weeks. Taken together, these 
data suggest a dysregulation of central serotonergic pathways 
as a consequence of obesity.61
The direct functional involvement of 5HT in the modula-
tion of feeding behavior was suggested by early experiments 
  examining the anorectic potency of fenfluramine.62,63 
Fenfluramine (3-trifluoromethyl-N-ethylamphetamine) is 
structurally similar to d-amphetamine, but fenfluramine is more 
potent as an anorectic agent without an abuse potential.64–66 
Fenfluramine is a racemic compound with its active enantiomer 
being the d-isomer or dexfenfluramine.67 The mechanism of 
action for dexfenfluramine is the release of 5HT (and to a 
much lesser extent NE), whereas amphetamine is less selective 
and releases NE and DA from nerve terminals. Fenfluramine, 
dexfenfluramine, and d-amphetamine are classified as monoam-
ine releasing agents, but specifically are transporter substrates 
causing the displacement of monoamines from   intracellular 
storage independent of neuronal activity.40,62,68 In addition, 
active metabolites of   fenfluramine and   dexfenfluramine 
(eg, nor-fenfluramines) act as agonists at postsynaptic sero-
tonin receptors to potentiate the serotonergic actions of the 
parent drugs.66,69 Dexfenfluramine also has actions to enhance 
energy expenditure since the body weight produced by the drug 
is greater than that achieved by pair-feeding animals.65,70,71 This 
enhanced energy expenditure partly occurs via increased fat 
oxidation.72 Fenfluramine was approved in 1973 and dexfen-
fluramine was approved in 1996 as   medications for treatment 
of obesity in the US. Fenfluramine and later dexfenfluramine 
were part of an “off-label”   combinational drug therapy 
with phentermine, an amphetamine analog stimulant FDA-
approved for the short-term (up to 3 months) treatment of 
obesity, and the drug combination was known as “fen-phen” 
or “dexfen-phen”.66,73 Although the combinational therapies 
were effective in the long-term management (up to 12 months) 
of obesity and were widely prescribed, the therapies were 
associated with a   significant increased risk of developing pri-
mary pulmonary hypertension and valvular heart disease.74–80 
These adverse events were discovered to be caused by 
  fenfluramine and dexfenfluramine and the two drugs were 
subsequently withdrawn from the market in 1997 at the FDA’s 
recommendation.81
Not only did experimental findings with fenfluramine 
and dexfenfluramine suggest that targeting the serotonergic 
  systems produced clinically significant body weight 
reductions, these drugs also implicated 5HT’s involvement 
in the inhibitory control of eating. Acute peripheral injections 
of fenfluramine and dexfenfluramine have been demonstrated 
to increase hypothalamic concentrations 5HT.82,83 Also, when 
dexfenfluramine is chronically administered to rodents it 
reduces meal sizes and meal duration, and progresses the 
behavioral sequence of satiety, suggesting that the drug acts on 
the physiological functions involved in the normal cessation 
of a meal.84–86 That is, when rats are allowed to eat until sati-
ety they display a temporal sequence of behaviors as meal 
consumption is terminating that begins with a reduction in 
eating followed by increases in grooming and other activities, 
and then a period of rest.84,85,87 This behavioral sequence is 
disrupted with amphetamine and food adulterated with bitter-
tasting quinine, suggesting the anorectic responses produced 
by these agents are mediated differently from those involved 
with satiety.85,88 Generally speaking, it has been demonstrated 
that serotonergic compounds, which specifically and dose-
dependently increase 5HT   signaling to reduce food intake, 
maintain the integrity of the behavioral satiety sequence at 
a related range of doses.84,85,89 Similar reductions in   eating 
rate and increased subjective satiety ratings have been 
demonstrated in human subjects administered fenfluramine 
and other serotonergic drugs, confirming the behavior 
  interpretations made in rodents.70,90–92 Correspondingly, 
certain pharmacological conditions that decrease CNS levels 
of 5-HT promote overeating.57 Centrally injected selective 
serotonin depleting agents, such as p-chlorophenylalanine or 
5,7-dihydroxytryptamine   pretreatment with desmethlyimip-
ramine, resulted in pronounced hyperphagia and increased 
body weight in rats.93,94
Sibutramine was approved for the long-term treatment 
of obesity by the FDA in November 1997 (coincidentally, 
dexfenfluramine was withdrawn in September, 1997). 
Sibutramine also increases the extracellular 5HT to reduce 
food intake, but does so by a different mechanism of action 
than dexfenfluramine. Acting as a NE and 5HT reuptake 
inhibitor, sibutramine (and its active metabolites) prevents the 
extracellular removal of monoamines and their effectiveness, 
and therefore is dependent on neuronal activity of 5HT neu-
rons. Using anorectic doses of fenfluramine or sibutramine 
in rats, the magnitude of release of 5HT in the hypothalamus 
was shown to be 10- to 15-fold higher with fenfluramine 
(3 mg/kg) than with sibutramine (10 mg/kg).82 The reduced 
magnitude of 5HT release with sibutramine is mediated, in Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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part, by indirect activation of somatodendritic autoreceptors, 
which modulate the intrinsic activity of 5HT neurons.82,95 
This autoreceptor inhibition is not evident with monoamine 
releasers (eg, fenfluramine or dexfenfluramine) because their 
mechanism of action is not dependent on neuronal activa-
tion.82 Sibutramine, similar to serotonin-selective reuptake 
inhibitors (SSRI), was believed to mediate its actions by 
increases in basal or tonic levels of 5HT with repeated 
treatment. It appears that autoreceptor desensitization in 
the dorsal raphe rather than increased 5HT actions in the 
terminal is more likely involved in the sustained actions of 
SSRIs, but this needs further delineation for the anorectic 
actions of sibutramine.38,96,97 It is worth noting that SSRIs 
do not have a sustained effect on weight loss, hence it has 
been concluded that the combined actions on the 5HT and 
NE transporters are needed for the weight loss efficacy of 
sibutramine.39,98,99
Sibutramine has been reported to improve glucose 
regulation and lipid profiles in obese subjects, but the 
enhancement of these factors appears to be a consequence of 
weight loss rather than the direct actions of sibutramine 
on metabolism.38,100 Sibutramine has been demonstrated, 
  however, to improve obesity-related energy expenditure. 
Dietary weight loss is accompanied by a decrease in energy 
expenditure, which tends to be an obstacle for optimal weight 
loss.101 Several studies have indicated that sibutramine 
attenuates the decline in energy expenditure that follows 
weight loss.102,103 The increased energy expenditure has 
been shown to be mediated by central modulation of sym-
pathetic outflow, the thermogenic effects being blocked by 
  antagonism of β3 adrenoceptor in rats.104 On the other hand, 
the effect of sibutramine on heart rate and blood pressure 
appears to be a paradoxical interplay between reduced central 
and increased peripheral sympathetic regulation, but this 
needs further clarification.56,105–108
The assortment of central and peripheral biological 
actions of 5HT is mediated by at least 14 different   classified 
receptors that are differentiated based on structure, function, 
and intracellular signaling.109,110 The two receptors most 
critically involved in the control of feeding behavior and body 
weight homeostasis are the 5HT1B and 5HT2C receptors.111 
Recent findings have also implicated 5HT2B receptors in 
the anorectic properties of dexfenfluramine; however, this 
receptor has been strongly implicated in the cardiopulmonary 
adverse effects of dexfenfluramine.112–114 The role of the 5HT2B 
receptor is likely to be a mechanism involved in potentiating 
5HT release from serotonergic neurons, but its feasibility as a 
target for obesity certainly requires further examination.112
The 5HT1B receptor (classified at one time as the 
human 5HT1Dβ receptor115,116) is a G-protein couple recep-
tor (GPCR) that negatively couples to adenylyl cyclase 
to inhibit cAMP formation. Like receptors of the 5HT1 
class, the 5HT1B receptor has a high affinity for 5HT and 
is encoded by a gene sequence without introns.110 Located 
on nerve terminals, the 5HT1B receptor functions as an 
autoreceptor to inhibit the release of 5HT from serotonergic 
neurons or as heteroreceptors to inhibit the release of other 
(nonserotonin) neurotransmitters.109,110,117 The involvement 
of the 5HT1B receptor in feeding behavior was initially 
implicated using preferential antagonists with affinity for 
the receptor, such as (+/−) cyanopindolol and methiothepin, 
to block the   anorectic actions of dexfenfluramine, whereas 
the selective agonist, CPP94235 (3-(1,2,5,6-tetrahydro-4-
pyridyl)-5-propoxypyrrolo[3, 2-b] pyridine), reduced meal 
size and decreased feeding duration.118–121 Further evidence 
for a role in feeding behavior was demonstrated with the 
generation of the 5HT1B receptor knockout mouse. Following 
administration of fenfluramine (3 or 10 mg/kg), for instance, 
5HT1B receptor knockout mice were unresponsive to its 
anorectic actions and demonstrated reduced or no neuronal 
activation in feeding related brain areas compared with wild 
types.122 It also has been reported that 5HT1B receptor knock-
out mice, compared with age-matched wild type mice, have 
higher body weights and consumed more food and water, 
but these findings are not consistently reported with 5HT1B 
knockout mice.122,123
The actions of the 5HT1B receptor in the CNS have 
been demonstrated to directly influence pathways involved 
in food intake and body weight homeostasis. Separate 
populations of neurons in arcuate nucleus (ARC) of the 
hypothalamus express the orexigenic peptides neuropeptide 
Y/agouti-related peptide (NPY/AgRP) or the precursor 
pro-opiomelanocortin (POMC) to the anorectic peptide 
alpha-melanocyte stimulating hormone (α-MSH). These two 
groups of neurons are activated or inhibited by other CNS 
pathways or peripheral circulating factors to control feeding 
behavior and energy expenditure. For example, the POMC-
containing neurons release α-MSH to acts on melanocortin 
(MC) MC3/MC4 receptors lead to downstream effects that 
reduce food intake and increase energy expenditure. Recip-
rocally, increases in food intake and reduction in energy 
expenditures are demonstrated following activation of adja-
cent NPY/AgRP neurons. While NPY acts on a distinct set of 
receptors, AgRP is an endogenous antagonist for MC3/MC4 
receptors.124–127 In a series of experiments it was determined 
5 HT1B receptors are expressed on AgRP neurons and 5HT Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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terminals are in close proximity to ARC neurons that contain 
AgRP.   Furthermore, it was demonstrated that CPP 94235, 
a   selective 5HT1B receptor agonist, reduces the membrane 
potential (ie, hyperpolarizes) of ARC neurons that express 
NPY/AgRP and reduces the inhibitory inputs on POMC neu-
rons.128 Moreover, mice with disruptions in the MC4 receptor 
were unresponsive to the anorectic effects of dexfenfluramine 
or CPP 94253.128 Such data strongly suggest that 5HT actions 
are mediated by the 5HT1B receptor signaling to increase the 
MC4 receptor-mediated melanocortin pathways.
In contrast to the 5HT1B receptor, the 5HT2C receptor 
is a GPCR with cellular excitatory activation that leads to 
the accumulation of inositol phosphates and downstream 
activation of phospholipase C. Originally classified as the 
5HT1C receptor based on its binding affinities for 5HT, the 
receptor was re-classified as 5HT2C after gene sequencing 
revealed it had introns in various coding regions and was 
structurally and functionally similar to receptors in the 5HT2 
class.110 Similar to 5HT1B, the role of the 5HT2C receptor 
was implicated in feeding by several experiments using 
preferential and selective agonist and antagonists.120,129,130 
Experiments utilizing 5HT2C receptor knockout mice have 
demonstrated hyperphagia and an obese phenotype.131–133 
These mice also are less responsive to the anorectic properties 
of dexfenfluramine (3 mg/kg) and preferentially selective 
agonists.132,134 It has been shown that the 5HT2C receptor 
mediates the activity of ARC neurons, in a mechanism that is 
complementary to that of the 5HT1B receptor. For instance in 
the ARC, the 5HT2C receptor was also found in up to 80% of 
POMC neurons and activation of the 5HT2C receptor increased 
the firing rate of POMC neurons. Upstream activation of MC 
receptors was also needed because dexfenfluramine action 
can be blocked by antagonism of MC3/MC4 receptors, while 
the anorectic responses of MTII, an MC3/MC4 receptor 
agonist, were indistinguishable between wild type and 5HT2C 
receptors knockout mice.135 Together with the findings for 
the 5HT1B receptor, this suggests that 5HT activates POMC 
neuron and inhibits NPY/AGRP to reduce the expression of 
feeding behaviors. Such findings support the pharmacological 
studies that suggest that the 5HT1B and 5HT2C receptors 
reduce food intake by independent mechanisms.136
Serotonin has also been implicated in glucose regulation 
by action at the 5HT2C receptor. Early findings with 5HT2C 
receptor knockout mice indicated that these animals had 
elevated fasted blood glucose and insulin levels and impaired 
glucose tolerance compared with wild types.133 Using the 
preferential, mCPP (m-chlorophenyl-piperazine), or the 
selective, BVT.X, 5HT2C ligands, it was demonstrated that 
5HT2C receptor compounds improved glucose homeostasis in 
diet-induced or mutant obese animals. This was accomplished 
by using low doses of the compounds, which did not affect 
food intake. The mechanisms were shown to be mediated by 
activation of POMC neurons and of downstream activation of 
MC4 receptors located in the intermediolateral cell nucleus of 
the spinal cord, suggesting 5HT2C receptor agonist alters sym-
pathetic outflow to improve glucose homeostasis.137 A similar 
mechanisms of MC4 activation to increase sympathetic 
outflow is speculated to account for the hyperthermic effects 
noted with several selective 5HT2C receptor agonists, but this 
has not been experimentally determined.138,139   Lorcaserin 
  (APD-356), a 5HT2C agonist, has not only completed a 
phase III study to determine effectiveness for the treatment of 
  obesity (BLOOM), but is also undergoing a phase III study for 
the management of obesity and glucose regulation outcomes 
in subjects with diabetes mellitus type II (BLOOM-DM).51 
Preliminary findings indicate improvements in fasting blood 
glucose levels and HbA1c levels in obese diabetic subjects 
treated with lorcaserin (10 mg twice daily).140
Chemistry and related 
pharmacology of sibutramine  
and lorcaserin
Sibutramine hydrochloride (BTS 54 524; N-1-(1-
[4-chlorophenyl]cyclobutyl)-3-methylbutyl-N,N-
  dimethylamine  hydrochloride  monohydrate)  is  a 
racemic compound that is structurally similar to other 
β-phenylethylamine drugs, such as metamphetamine, 
phentermine, and dexfenfluramine (see Figure 1).41,141 It is 
suggested that the chlorine on the 4 position of the phenyl 
HO
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Figure  1  Chemical  structure  of  serotonin  (5-hydroxytryptamine;  5HT)  and 
serotonergic compounds that have been used for, or have the potential to treat, 
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ring imparts affinity for the serotonin transporter, since 
it has been demonstrated that a halogenated-substituted 
phenyl rings is needed for SSRI specificity.142 In vitro and 
in vivo data have demonstrated that sibutramine weakly 
inhibits monoamine uptake in human and rat tissue.40,143,144 
For instance, in vitro inhibition (half maximal inhibitory 
concentration, IC50) in rat brain tissue of sibutramine is 
2.17 µM for NE, 477 µM for 5HT, and 10.8 µM for DA.143 
Sibutramine, though, is metabolized by the liver primarily 
by the P450 isozyme CYP2B6 into two active metabolites 
that are more potent monoamine inhibitors than the parent 
compound.40,143–145 Sibutramine metabolism takes place by a 
series of demethylations, first to the primary (M1) metabo-
lite (BTS 54 354; N-1-(1-[4-chlorophenyl] cyclobutyl]-3- 
methylbutyl-N-methylamine hydrochloride monohydrate) and 
then to secondary (M2) metabolite (BTS 54 505; N-1-(1-[4-
chlorophenyl] cyclobutyl]-3-methylbutylamine hydrochloride 
monohydrate). The M1 metabolite demonstrated an in vitro 
inhibition of 0.14 µM for NE, 3.9 µM for 5HT, and 0.16 µM 
for DA, whereas the M2 metabolite in vitro inhibition was 
0.06 µM for NE, 5.1 µM for 5HT, and 0.31 µM for DA.143 
In vivo data indicate the two active metabolites of sibutramine 
are approximately equipotent for NE and 5HT inhibition 
with inactive inhibition for DA.40,143 The active metabolites 
display a similar degree of inhibition for 5HT as SSRI 
compounds.40,83 In humans the elimination half-life of oral 
administration of sibutramine is 1.1 hours while the half-lives 
of the active metabolites are much longer, at 14 hours and 
16 hours for M1 and M2, respectively.146 In a recent positron 
emission tomography study in human subjects (n = 11), it was 
determined that brain serotonin transporter occupancy was 
significantly positively correlated (r2 = 0.59, P = 0.003) with 
plasma M2 levels, suggesting that 5HT inhibition is mediated 
predominately by M2.147
Lorcaserin hydrochloride [(1R)-8-chloro-2,3,4,5 
tetrahydro-1-methyl-1H-3-benzazepine] is a substituted 
3-benzazepine, structurally resembling serotonin and 
  nor-dexfenfluramine (dexfenfluramine   metabolite). 
The  compound  is  synthesized  from  a  substituted 
phenylethylamine precursor with the chlorine substitution 
at the 8-position yielding high affinity and selectivity for the 
5HT2C receptor.148 In fact, lorcaserin demonstrated ∼10-fold 
higher affinity for the human 5HT2C receptor compared 
with the 5HT2A and 5HT2B receptors (Ki values of 15 nM, 
112 nM, and 174 nM, respectively) and .40-fold higher 
affinity compared with other 5HT receptors.149 Using in vitro 
functional assays examining inositol phosphate accumulation 
in HEK cells transfected with specific human 5HT   receptors, 
lorcaserin was 18-fold and 104-fold more potent at the 5HT2C 
than at the 5HT2A and 5HT2B receptors, respectively.149 
  Lorcaserin is metabolized by the liver and the M1 metabolite 
is a sulfamate, which is inactive with no apparent affinity for 
any of the 5HT2 receptors.149,150 The elimination half-life of 
orally administered lorcaserin in humans is 11.1 hours and 
the half-life of the M1 metabolite is 41.3 hours.51
Clinical efficacy studies  
for sibutramine and lorcaserin
The efficacy of sibutramine for weight loss with diet 
intervention was tested in several clinical trials in obese 
subjects. In one double-blind randomized trial, sibutramine 
at 5 mg or 20 mg once daily was compared with placebo in 
3 groups of subjects. Notably, medications were administered 
over an 8-week period during the holiday season with Thanks-
giving falling between week 2 and 3, Christmas between week 
6 and 7, and New Year’s falling on weeks 7 and 8. Weight loss 
in the 5 mg sibutramine group (n = 18) was approximately 
2% greater than in the placebo group (n = 19), while weight 
loss in the 20 mg sibutramine group (n = 18) was approxi-
mately 4% greater than in placebo.151 In another multi-center 
double-blind randomized study using a wider dose range of 
sibutramine (6 doses between 1 and 30 mg once daily) in a 
large sample size (n = 1043) for a longer duration (24 weeks) 
the efficacy of sibutramine was further assessed. There was a 
dose-dependent relationship for weight loss with sibutramine 
over the trial. Doses of 1 mg or 5 mg produced an approxi-
mately 2% greater weight loss than in those individuals 
receiving placebo, while doses of 10 mg, 15 mg, 20 mg, and 
30 mg produced an approximately 4% to 7% greater weight 
loss than in placebo. The categorical efficacy with 10 to 
30 mg of sibutramine demonstrated that .58% of the popu-
lation maintained 5% weight loss from baseline and .17% 
of the population maintained 10% weight loss from baseline 
over the 24 weeks. After the 24-week treatments there was a 
single-blind phase “washout” period of 6 weeks during which 
placebo was administered to all subjects. At the end of this 
period subjects regained weight, those losing the most dur-
ing treatment regaining the most weight during the washout 
period.152 In a smaller study (n = 173) conducted in the same 
fashion, after a 6-week washout period from 24 weeks of 
sibutramine treatment $40% of the subjects from the 10- to 
30-mg sibutramine group maintained a 5% weight loss from 
baseline and $12% maintained a 10% weight loss from base-
line.153 The greatest amount of weight loss with sibutramine 
appears to occur during the first 12 weeks of treatment, weight 
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In a meta-analysis that examined the data from 10 double-blind 
randomized control studies (n = 2623) it was revealed that 
long-term treatment (1 year or more) with sibutramine 
(10–20 mg once daily) lost 3.7% to 5.0% more weight than 
individuals receiving placebo. In addition, from the same 
data set, approximately 35% more individuals receiving 
sibutramine than subjects receiving placebo maintained 
a $5% weight loss and 18% more than placebo maintained 
a $10% weight loss from baseline. In comparison, data 
from 13 studies (n = 4948) found that the FDA-approved 
gastrointestinal lipase inhibitor orlistat produced a weight 
loss 2.9% to 3.4% greater than in individuals receiving 
placebo. Proportionally, only approximately 21% more 
individuals taking orlistat maintained a $5% weight loss and 
approximately 12% maintained a $10% weight loss from 
baseline.17 Sibutramine was also more effective at reducing 
body weight directly compared with another serotonergic 
drug used to treat obesity, dexfenfluramine. This compari-
son was only with a single dose of both drugs, rather than 
a range of doses. For this study, 2 groups of obese subjects 
received either sibutramine (10 mg once daily; n = 112) or 
dexfenfluramine (15 mg twice daily; n = 114) for 12 weeks. 
Because there was no placebo control group, weight loss was 
compared with baseline values within groups. Sibutramine 
treatment produced a 5.4% weight loss, dexfenfluramine a 
4.2% weight loss. Sibutramine was also associated with a 
greater proportion of subjects maintaining a $5% weight 
loss for the study duration, (46% compared with 34% for 
dexfenfluramine).154
The first double-blind placebo controlled randomized 
clinical trial for lorcaserin examined the efficacy of three 
doses (10 mg or 15 mg once daily, 10 mg twice daily) in obese 
individuals (n = 469) for 12 weeks. For this study no diet or 
lifestyle intervention strategy was endorsed by the experiment-
ers for the study participants. Lorcaserin produced a dose-
dependent reduction in weight, with a 1.4%, 2.3%, and 3.1% 
greater weight loss than placebo for the 10 mg (once daily), 
15 mg (once daily), and 10 mg (twice daily) doses, respec-
tively. The proportion of subjects losing $5% body weight 
from baseline was 12.8% (10 mg once daily), 19.5% (15 mg 
once daily), and 31.2% (10 mg twice daily).150 In a multicenter 
double-blind placebo-controlled randomized clinical trial in 
a larger number of obese subjects (n = 3182), the efficacy of 
lorcaserin (10 mg twice daily) was compared with placebo 
for 1 to 2 years. In addition to including diet and lifestyle 
interventional strategies, the efficacy of lorcaserin was fur-
ther assessed by having a randomized portion of subjects in 
lorcaserin groups reassigned to placebo at the end of year 1 
and followed for an additional 1 year. Efficacy, therefore, was 
assessed in 2 groups, lorcaserin compared with placebo, in 
year 1 and 3 groups at the end of year 2, lorcaserin compared 
with placebo compared with lorcaserin–placebo. At the end 
of year 1, lorcaserin resulted in 4.0% greater weight loss than 
placebo. A $5% weight loss from baseline body weight was 
achieved in 47.5% of subjects receiving   lorcaserin compared 
with 20.3%   receiving placebo. Only 22.6% of the lorcaserin 
group compared with 7.7% of the placebo maintained $10% 
weight loss from baseline. At the end of year 2, the degree of 
weight loss was maintained in the group continuing to receive 
lorcaserin, but weight gain was apparent in the group that 
was switched to placebo. The group that received lorcaserin–
placebo had an identical weight loss to the placebo group by 
28 weeks after the reassignment.50 There are no reported stud-
ies, either experimentally or from a meta-analysis, comparing 
the weight loss efficacy of lorcaserin with other medications 
for the treatment of obesity.
Safety and tolerability
Medications acting on serotonergic systems have received 
considerable scrutiny for cardiopulmonary complications 
because of the increased incidence of primary pulmonary 
hypertension and valvulopathies associated with earlier obesity 
medications, fenfluramine and dexfenfluramine. Sibutramine 
or lorcaserin has not been associated with any reported cases 
of confirmed pulmonary hypertension. In addition, pulmonary 
artery pressure has not been demonstrated to change with 
long-term treatment with either medication.50,155 Likewise, 
sibutramine has not been demonstrated to influence cardiac 
valve function or result in any evident valvulopathies.156 In 
a multicenter study examining weight loss efficacy of lorca-
serin (see above), the occurrence of valvulopathy at 52 weeks 
was 2.7% in the subjects   receiving lorcaserin (10 mg twice 
daily) and 2.3% in the placebo group.50 Preliminary find-
ings at 52 weeks in the BLOOM-DM (n = 604) study for 
lorcaserin, however, have shown that the incidence of valvu-
lopathies was 2.9% in subjects receiving lorcaserin (10 mg 
twice daily) and 0.5% in the placebo group.140 Although the 
study was not   powered to determine a statistical difference in 
  valvulopathies between groups, this almost 6-fold difference 
in incidence rates certainly raises concerns that likely need 
to be addressed in future lorcaserin studies. Notwithstanding, 
other   documented safety issues and potential health risks 
have resulted in the withdrawal of sibutramine and the FDA 
rejection of lorcaserin.
At the time of FDA approval for sibutramine it was well 
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rate and blood pressure. Initially, the NDA for sibutramine 
contained 5 doses (5 mg, 10 mg, 15 mg, 20 mg, and 30 mg 
once daily). Because of the potential dose-dependent 
  cardiovascular risk balanced against the potential benefit 
for the treatment of obesity, only 3 doses (5 mg, 10 mg, and 
15 mg once daily) were approved by the FDA in 1997.152,157 
Sibutramine, though, carries a bold-type warning that blood 
pressure and heart rate should be   monitored in patients receiv-
ing the drug and it is contraindicated in individuals with a 
history of coronary artery disease, congestive heart failure, 
arrhythmias, or stroke.47 In a meta-analysis of 7 double-
blind randomized control studies examining sibutramine 
treatment ($1 year) in obese individuals, the drug was 
found to increase systolic blood pressure by 1.7 mm Hg, 
diastolic pressure by 2.4 mm Hg, and resting heart rate by 
4.5 bpm compared with placebo.17 The increase in heart 
rate and blood pressure is likely to influence cardiovascular 
function. The recently completed SCOUT trial was con-
ducted in 16 countries, initially enrolling .10,000 subjects, 
to examine the long-term effects (mean treatment was 
3.4 years) of sibutramine on cardiovascular outcomes in 
overweight and obese subjects. Unlike other clinical studies 
with sibutramine, eligible subjects had to have a history of 
cardiovascular disease and/or diabetes mellitus type II with 
one risk factor for cardiovascular disease. As previously 
demonstrated, sibutramine was associated with an increase 
in blood pressure and heart rate; the drug also resulted in an 
increased rate of nonfatal myocardial infarction (+0.9%) and 
stroke (+0.7%).48 The most frequently reported adverse events 
with sibutramine are dry mouth, insomnia, and constipation. 
Typically, these events are dose-related, the 15 mg dose hav-
ing a placebo-subtracted reported frequency of ∼20%, ∼5%, 
and ∼5%, respectively.47,152
The major safety concerns for the lorcaserin (10 mg 
twice daily) NDA are findings from the carcinogenicity 
studies in rodents. In particular, 2-year treatment with 
lorcaserin resulted in a higher combined incidence rate of 
mammary fibroadenomas and adenocarcinomas in female 
rats at the 10 mg/kg, 30 mg/kg, and 100 mg/kg compared 
with vehicle-treated animals. In the male rats at the 30 mg/kg 
and 100 mg/kg doses, there was also a higher incidence rate 
of combined mammary tumors and skin benign fibromas. 
In addition, male rats receiving the 100 mg/kg dose showed 
an increased incidence rate of astrocytomas, squamous 
carcinomas, Schwannomas, combined hepatocullular 
neoplasms, and follicular cell adenomas. Over the 2-year 
study, the survival rate for both genders of rats was strongly 
negatively influenced by lorcaserin. In fact, the female 
  survival rate was 18.4% for 10 mg/kg, 7.7% for 30 mg/kg, 
and 0% for 100 mg/kg while the vehicle survival rate was 
35%. Only the high dose appeared to influence the survival 
rate of males, which was 5.3% compared with 33.8% of the 
vehicle group. Necropsy findings confirmed that lorcaserin-
induced tumors were associated with the excessive mortality 
observed with both genders of rats.51 In a multicenter phase 
III clinical trial with lorcaserin (10 mg twice daily) treatment 
($1 year) the most frequently subject-reported adverse 
event was headache (7.2% in lorcaserin compared with 
4.3% in placebo). The frequency of headaches in the treated 
population, as well as other less frequent subject-reported 
adverse events, had a tendency to decrease with lorcaserin 
treatment length.50
Both sibutramine and lorcaserin appear to be well 
tolerated by obese subjects. The reported 1-year attrition rate 
appears to be about 35% for sibutramine and about 45% for 
lorcaserin.17,50 Certainly more long-term studies are needed 
to determine accurate drop-out and nonresponder rates with 
lorcaserin.
Patient-focused perspectives
Improvements in the quality of life, attitudes, and mood have 
been demonstrated to occur in overweight or obese patients 
with weight loss.158–160 Long-term pharmacotherapy for 
obesity, including sibutramine and lorcaserin, at doses that 
are effective at reducing body weight are also associated with 
improvements in the quality of life and subjective attitude 
scores.17,50,161 What is unclear is whether the medications 
per se or the medication-associated additional weight loss is 
responsible for the improvement in quality of life and patient 
attitude. Experiments addressing this issue with sibutramine 
have had mixed findings. In one study (n = 376), 6-month 
treatment with sibutramine (10 mg) combined with high-
frequency contact with a dietician resulted in greater weight 
loss than the group receiving sibutramine only. Although 
quality of life assessment was significantly improved from 
baseline (ie, before intervention and/or sibutramine), there 
was no difference in scores between groups.161 This implies 
that sibutramine treatment alone had an impact on quality 
of life not directly related to the degree of weight loss. In 
contrast, a 12-month study (n = 236) in obese subject with 
diabetes mellitus type II, treatment with sibutramine (15 mg) 
produced significantly greater weight loss (7.3%) than the 
placebo group (2.4%), but did not change health-related 
quality of life ratings.162 Sibutramine (15 mg) treatment 
compared with placebo for 6 months also failed to improve 
quality of life scores in a population of bulimic patients Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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(n = 304), but effectively reduced body weight and reduced 
the severity and frequency of binge eating episodes.163
Conclusion
Pharmacotherapy would greatly benefit effective interven-
tional nonsurgical strategies for the management of obesity. 
As a result of the US and European drug regulatory agencies 
scrutinizing more closely the approval and the continued 
use of these medications, the approved drug market for the 
treatment of obesity has been reduced to one medication, 
orlistat. Aside from the frequently reported gastrointestinal 
disturbances and the well-documented modest long-term 
drug-associated weight loss (∼3%), orlistat is relatively 
safe. The continued approval of orlistat as a prescribed 
and over-the-counter treatment for obesity demonstrates 
that the weight-loss efficacy standards of the FDA and 
European regulatory agencies, 5% drug-associated weight 
loss and .35% of the treated population losing 5% of body 
weight, are not a contingent criteria for drug approval. 
The rationale in orlistat’s case is that any safe weight loss is 
beneficial. In order for drug manufacturers to develop and 
screen potential medications that receive approval by these 
agencies, the efficacy guidelines should be clearly revised 
to include the acceptable margin of drug-associated weight 
loss. In doing so and under the “any weight loss is beneficial” 
premise, this is likely to produce pharmacotherapy with 
reduced efficacy for weight loss, but with fewer and less 
severe adverse effects.
While drug regulatory agencies examine the   risk–benefit 
analysis of each approved and proposed medication for the 
treatment of obesity, the unapproved herbal and “natural” 
dietary supplements consumer market is driven almost 
entirely by demand. In a study of 35,000 US adults approxi-
mately 34% had used dietary supplements for weight loss and 
approximately 50% of the entire sampled population overes-
timated the safety and efficacy of these unapproved weight 
loss supplements.164 Herbal and dietary supplements reduce 
appetite and promote weight loss by various mechanisms, 
some of which are not clearly defined or systematically 
examined.165 A number of these supplements (eg, “bit-
ter orange” and other stimulants) promote weight loss by 
increasing autonomic activity (including increases in rest-
ing heart rate and blood pressure).166,167 Unlike patients that 
received sibutramine, however, individuals taking dietary 
supplements are likely not being observed regularly by a 
health care provider to monitor heart rate and blood pressure. 
Indeed, the risk of nonfatal myocardial infarction and stroke 
has not been assessed with herbal remedies and dietary 
supplements used to suppress appetite. In the past, the FDA 
has been reactive, rather than proactive, in regulating diet 
supplements (eg, ephedra). Taken in the broader context of a 
demonstrated need and willingness of the consumer market 
for substances that promote weight loss and the availability 
of the unregulated alternatives, an argument can be made that 
withdrawal of sibutramine is likely to be more detrimental to 
the overweight and obese population than the risks associated 
with sibutramine treatment. Another option not exercised by 
the FDA and other regulatory agencies is to include a “black 
box” warning on sibutramine, which appears to be more 
than reasonable considering the medication has been on the 
US market for 13 years. The data from the SCOUT clinical 
trial should be considered “worst case scenario”, since 
the primary outcome event was the incidence of   nonfatal 
  myocardial infarction, nonfatal stroke resuscitation after 
cardiac arrest, and cardiovascular death in subjects with a 
history of and/or risk factors for cardiovascular disease. What 
is also unclear is whether the cardiovascular risks associated 
with sibutramine are long lasting or permanent after cessation 
of sibutramine treatment. Overall, the rationale of the FDA 
for the withdrawal of sibutramine seems unwarranted and 
unnecessary considering the medication, certainly since its 
approval in 1997, has always been associated with increases 
in cardiovascular-related adverse effects.
In contrast, the decision of the FDA not to approve 
  lorcaserin pending further data is entirely reasonable. 
The carcinogenicity findings in rats are too difficult to rectify 
without a defined mechanism of action, as is the related low 
survival rate. The low survival rate with lorcaserin is rather 
surprising considering that calorie restriction with weight 
loss decreases mortality and leads to a longer life span.168,169 
A recent study re-examining the toxicology data from a 
2-year study in rodents (n = 520 mice and n = 520 rats) found 
that sibutramine had no effect (either positive or negative) 
on longevity or mortality rate.170 In the toxicology studies 
with lorcaserin, on the other hand, the reduced survival rate 
trends exactly with the dose-dependent drug-induced tumor 
load, suggesting the cause of the increased mortality is likely 
a result of lorcaserin carcinogenicity. Further testing is 
undoubtedly needed to clearly determine whether the tumor 
burden was caused by lorcaserin or was related to toxicity as 
a result of the maximum tolerated dose being exceeded.
Therapeutically targeting the serotonergic systems 
will continue to be a viable approach for the treatment of 
obesity. This does not mean that other neurotransmitter 
systems or even combination therapies may prove to be more 
efficacious in combating obesity with fewer side effects. Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Even so, serotonin actions in producing subjective feelings 
of satiety by modulation of the neural mechanisms of appetite 
are beneficial not only for reducing and maintaining body 
weight, but also for controlling eating behavior. Because of 
the adverse effects associated with nonspecific serotonin 
drugs, such as dexfenfluramine and sibutramine, the recent 
direction of drug development has focused on specific 
receptor agonists. Recent findings with lorcaserin, the 5HT2C 
agonist, need further clarification while a specific 5HT1B 
receptor agonist has yet to be clinically developed. Although 
the immediate hope for a serotonin-based pharmacotherapy 
seems remote, given what is known about the serotonin 
systems and the control of appetite, the long-term probability 
is that a new serotonin-based therapeutic will emerge. In the 
short-term, the landscape of obesity pharmacotherapy would 
be better served by a clarification of reasonable efficacy 
standards by regulatory agencies.
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